PCVX

Vaxcyte, Inc.

68.79 USD
+0.03 (+0.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vaxcyte, Inc. stock is up 12.72% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 May 16:34 19 Jul, 2024 110.00 PUT 8 179
03 May 16:40 19 Jul, 2024 115.00 PUT 6 49
03 May 16:54 19 Jul, 2024 115.00 PUT 12 49
03 May 17:57 19 Jul, 2024 115.00 PUT 6 49
03 May 17:58 19 Jul, 2024 110.00 PUT 6 179
07 May 15:00 19 Jul, 2024 115.00 PUT 51 97
07 May 15:00 19 Jul, 2024 115.00 PUT 6 97
16 May 15:00 19 Jul, 2024 75.00 CALL 500 308
16 May 15:01 17 May, 2024 65.00 CALL 491 497
16 May 18:15 18 Oct, 2024 90.00 PUT 14 19

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.

  • Cantor Fitzgerald
    Thu May 9, 11:12
    buy
    confirm
  • Needham
    Thu May 9, 06:43
    buy
    confirm